Dren Bio Private Financing

Dren Bio, a privately held clinical-stage biotechnology company based in San Carlos, Calif. developing first-in-class antibody therapeutics for cancer, autoimmune and other serious diseases, closed an oversubscribed $350.0 million private financing. The round was co-led by Juvia Group and Lightspeed Venture Partners with participation from an expanded syndicate of new investors including Mirae Asset Capital Life Science, General Catalyst and Cormorant Asset Management [list truncated in provided excerpt]. The excerpt does not disclose a round designation [e.g., Series A/B], valuation, revenue/client/employee metrics, or specific planned use of proceeds.